^
    Back
    Association details:
    Biomarker:HER-2 L755S
    Cancer:Triple Negative Breast Cancer
    Drug:Nerlynx (neratinib) (EGFR inhibitor, HER2 inhibitor, HER4 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    New
    Source:
    J Natl Compr Canc Netw
    Title:

    HER2 mutated breast cancer responds to treatment with single agent neratinib, a second generation HER2/EGFR tyrosine kinase inhibitor

    Excerpt:
    This patient’s cancer had a HER2 L755S mutation....After 11 months, her cancer progressed and treatment with neratinib plus capecitabine produced another disease response...
    Secondary therapy:
    capecitabine
    DOI:
    https://doi.org/10.6004/jnccn.2015.0131
    Evidence Level:
    Sensitive: C4 – Case Studies
    New
    Source:
    J Natl Compr Canc Netw
    Title:

    HER2 mutated breast cancer responds to treatment with single agent neratinib, a second generation HER2/EGFR tyrosine kinase inhibitor

    Excerpt:
    This patient’s cancer had a HER2 L755S mutation and she had a partial response from neratinib monotherapy. This response markedly improved the patient’s performance status and quality of life.
    DOI:
    https://doi.org/10.6004/jnccn.2015.0131